<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>PhaseII | Kristian Brock</title>
    <link>/tags/phaseii/</link>
      <atom:link href="/tags/phaseii/index.xml" rel="self" type="application/rss+xml" />
    <description>PhaseII</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><lastBuildDate>Fri, 27 Dec 2019 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/img/icon-192.png</url>
      <title>PhaseII</title>
      <link>/tags/phaseii/</link>
    </image>
    
    <item>
      <title>PePS2</title>
      <link>/project/peps2/</link>
      <pubDate>Fri, 27 Dec 2019 00:00:00 +0000</pubDate>
      <guid>/project/peps2/</guid>
      <description>&lt;p&gt;PePS2 is a phase II trial of pembrolizumab in performance status 2 non-small-cell lung cancer patients.
It is run by the &lt;a href=&#34;https://www.birmingham.ac.uk/research/activity/mds/trials/crctu/&#34;&gt;Cancer Research UK Clinical Trials Unit&lt;/a&gt;.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia - The CLARITY Study</title>
      <link>/publication/clarity-results/</link>
      <pubDate>Thu, 11 Jul 2019 00:00:00 +0000</pubDate>
      <guid>/publication/clarity-results/</guid>
      <description>&lt;p&gt;This publication is important to me because Clarity was my first successful grant application.
It is a simple trial with modest sample size but the results are absolutely amazing, with an iwCLL response rate of 89% and minimum disease negative status achieved in the peripheral blood of 53% of patients.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
